These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

139 related items for PubMed ID: 17924396

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Novel extended and branched N-terminal analogs of VIP.
    Dangoor D, Rubinraut S, Fridkin M, Gozes I.
    Regul Pept; 2006 Nov 15; 137(1-2):42-9. PubMed ID: 16962672
    [Abstract] [Full Text] [Related]

  • 3. Design and development of a vasoactive intestinal peptide analog as a novel therapeutic for bronchial asthma.
    Bolin DR, Michalewsky J, Wasserman MA, O'Donnell M.
    Biopolymers; 1995 Nov 15; 37(2):57-66. PubMed ID: 7893947
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. A lymphocyte-generated fragment of vasoactive intestinal peptide with VPAC1 agonist activity and VPAC2 antagonist effects.
    Summers MA, O'Dorisio MS, Cox MO, Lara-Marquez M, Goetzl EJ.
    J Pharmacol Exp Ther; 2003 Aug 15; 306(2):638-45. PubMed ID: 12750439
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Spatial approximation between the C-terminus of VIP and the N-terminal ectodomain of the VPAC1 receptor.
    Ceraudo E, Tan YV, Couvineau A, Lacapere JJ, Laburthe M.
    Ann N Y Acad Sci; 2006 Jul 15; 1070():180-4. PubMed ID: 16888162
    [Abstract] [Full Text] [Related]

  • 10. Hexanoylation of a VPAC2 receptor-preferring ligand markedly increased its selectivity and potency.
    Langer I, Gregoire F, Nachtergael I, De Neef P, Vertongen P, Robberecht P.
    Peptides; 2004 Feb 15; 25(2):275-8. PubMed ID: 15063009
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Effect of positive charge in VIP 16gamma-glutamyl diamino derivatives on hVPAC1 and hVPAC2 receptor function.
    de Maria S, Metafora V, Metafora S, Ravagnan G, Cartení M, Pontoni G, Facchiano A, Lepretti M, Severino B, Caliendo G, Santagada V, Langer I, Robberecht P.
    J Pept Sci; 2008 Jan 15; 14(1):102-9. PubMed ID: 17883247
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Characterization of the new photoaffinity probe (Bz2-K24)-VIP.
    Tan YV, Couvineau A, Lacapere JJ, Laburthe M.
    Ann N Y Acad Sci; 2006 Jul 15; 1070():575-80. PubMed ID: 16888228
    [Abstract] [Full Text] [Related]

  • 17. Liposomal vasoactive intestinal peptide for lung application: protection from proteolytic degradation.
    Stark B, Andreae F, Mosgoeller W, Edetsberger M, Gaubitzer E, Koehler G, Prassl R.
    Eur J Pharm Biopharm; 2008 Sep 15; 70(1):153-64. PubMed ID: 18555674
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Photoaffinity labeling demonstrates physical contact between vasoactive intestinal peptide and the N-terminal ectodomain of the human VPAC1 receptor.
    Tan YV, Couvineau A, Van Rampelbergh J, Laburthe M.
    J Biol Chem; 2003 Sep 19; 278(38):36531-6. PubMed ID: 12807902
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.